AlphaRx Inc. Enters A Collaboration To Develop Novel Compounds For Central Nervous System Disorders

AlphaRx Inc. (OTC BB: ALRX), an emerging biopharmaceutical company, announced today that it has entered into a collaboration with PharmaSeed Ltd. of Israel, a bio-pharmaceutical company specializing in drug discovery and early development phases for the development of new drugs for the potential treatment of CNS disorders such as stroke and multiple sclerosis.

MORE ON THIS TOPIC